Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 4
2007 2
2008 4
2009 5
2010 9
2011 18
2012 22
2013 15
2014 16
2015 17
2016 23
2017 27
2018 39
2019 26
2020 27
2021 49
2022 47
2023 56
2024 19

Text availability

Article attribute

Article type

Publication date

Search Results

370 results

Results by year

Filters applied: . Clear all
Page 1
Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C, Yanagihara S, Otsuka A. Nakashima C, et al. Allergol Int. 2022 Jan;71(1):40-46. doi: 10.1016/j.alit.2021.10.004. Epub 2021 Nov 21. Allergol Int. 2022. PMID: 34815171 Free article. Review.
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. ...Therefore, the emergence of these topical and oral JAK inhibitors would be regarded as an innovation in the treatment of atopic dermatitis....
Atopic dermatitis (AD) is characterized by chronic, eczematous, severe pruritic skin lesions. ...Therefore, the emergence of t …
The IL-4, IL-13 and IL-31 pathways in atopic dermatitis.
Dubin C, Del Duca E, Guttman-Yassky E. Dubin C, et al. Expert Rev Clin Immunol. 2021 Aug;17(8):835-852. doi: 10.1080/1744666X.2021.1940962. Epub 2021 Jul 21. Expert Rev Clin Immunol. 2021. PMID: 34106037 Review.
Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. ...A literature search was conducted by querying Scopus, Google Scholar, PubMed, and Clinicaltrials.gov up to January 2021 using combinations of the search terms 'IL-4' 'IL-13' 'IL-31 …
Introduction: Atopic dermatitis (AD) is the most common inflammatory skin disease. ...A literature search was conducted by que …
Peripheral itch sensitization in atopic dermatitis.
Tominaga M, Takamori K. Tominaga M, et al. Allergol Int. 2022 Jul;71(3):265-277. doi: 10.1016/j.alit.2022.04.003. Epub 2022 May 25. Allergol Int. 2022. PMID: 35624035 Free article. Review.
The pathogenesis of atopic dermatitis is thought to be initiated by a lowering of the itch threshold due to dry skin. ...Therefore, controlling itch is essential for the treatment of atopic dermatitis. In this review, we summarize and discuss advances …
The pathogenesis of atopic dermatitis is thought to be initiated by a lowering of the itch threshold due to dry skin. ...There …
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, Suprun M, Estrada Y, Xu H, Peng X, Silverberg JI, Menter A, Krueger JG, Zhang R, Chaudhry U, Swanson B, Graham NMH, Pirozzi G, Yancopoulos GD, D Hamilton JD. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019 Jan;143(1):155-172. doi: 10.1016/j.jaci.2018.08.022. Epub 2018 Sep 5. J Allergy Clin Immunol. 2019. PMID: 30194992 Free article. Clinical Trial.
BACKGROUND: Dupilumab is an IL-4 receptor alpha mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as demonstrated by its efficacy in patients with atopic/allergic diseases. OBJECTIVE: This placebo-controlled, double-blind trial (NCT0197 …
BACKGROUND: Dupilumab is an IL-4 receptor alpha mAb inhibiting signaling of IL-4 and IL-13, key drivers of type 2-driven inflammation, as de …
Updated Review on Treatment of Atopic Dermatitis.
Armario-Hita JC, Galán-Gutiérrez M, Dodero-Anillo JM, Carrascosa JM, Ruiz-Villaverde R. Armario-Hita JC, et al. J Investig Allergol Clin Immunol. 2023 Jun;33(3):158-167. doi: 10.18176/jiaci.0906. J Investig Allergol Clin Immunol. 2023. PMID: 37318771 Free article. Review.
Atopic dermatitis (AD) is a chronic or chronically recurrent Inflammatory dermatosis associated with multiple triggers that has a complex pathophysiological mechanism. ...
Atopic dermatitis (AD) is a chronic or chronically recurrent Inflammatory dermatosis associated with multiple triggers that ha …
New and Emerging Systemic Treatments for Atopic Dermatitis.
Newsom M, Bashyam AM, Balogh EA, Feldman SR, Strowd LC. Newsom M, et al. Drugs. 2020 Jul;80(11):1041-1052. doi: 10.1007/s40265-020-01335-7. Drugs. 2020. PMID: 32519223 Free PMC article. Review.
Atopic dermatitis (AD) is a prevalent inflammatory skin condition that, depending on its severity, can cause enormous morbidity. ...
Atopic dermatitis (AD) is a prevalent inflammatory skin condition that, depending on its severity, can cause enormous morbidit …
Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.
Beck LA, Cork MJ, Amagai M, De Benedetto A, Kabashima K, Hamilton JD, Rossi AB. Beck LA, et al. JID Innov. 2022 Apr 26;2(5):100131. doi: 10.1016/j.xjidi.2022.100131. eCollection 2022 Sep. JID Innov. 2022. PMID: 36059592 Free PMC article. Review.
Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple interacting systems. ...
Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple interacting systems. ...
IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin.
Hashimoto T, Yokozeki H, Karasuyama H, Satoh T. Hashimoto T, et al. J Allergy Clin Immunol. 2023 Mar;151(3):737-746.e6. doi: 10.1016/j.jaci.2022.11.009. Epub 2022 Nov 19. J Allergy Clin Immunol. 2023. PMID: 36410530
BACKGROUND: IL-31 is a type 2 cytokine involved in the itch sensation in atopic dermatitis (AD). The cellular origins of IL-31 are generally considered to be T(H)2 cells. ...
BACKGROUND: IL-31 is a type 2 cytokine involved in the itch sensation in atopic dermatitis (AD). The cellular origins of IL-31 …
Pathogenesis of Atopic Dermatitis: Current Paradigm.
Furue M, Ulzii D, Vu YH, Tsuji G, Kido-Nakahara M, Nakahara T. Furue M, et al. Iran J Immunol. 2019 Jun;16(2):97-107. doi: 10.22034/IJI.2019.80253. Iran J Immunol. 2019. PMID: 31182684 Free article. Review.
Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. ...Clinical efficacy of the anti-IL-4 receptor antibody dupilumab implies that type 2 cytokines IL-4 and IL-13 have pivotal roles in atopic inflammation. T …
Atopic dermatitis (AD) is characterized by skin inflammation, barrier dysfunction and chronic pruritus. ...Clinical efficacy o …
JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
Huang IH, Chung WH, Wu PC, Chen CB. Huang IH, et al. Front Immunol. 2022 Dec 8;13:1068260. doi: 10.3389/fimmu.2022.1068260. eCollection 2022. Front Immunol. 2022. PMID: 36569854 Free PMC article. Review.
Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with heterogeneous manifestations that can substantially affect patients' quality of life. ...
Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with heterogeneous manifestations that can subs …
370 results